Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$10,000.

  • 4D Molecular Therapeutics' Gains from Investment Securities fell 100.10% to -$10,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year decrease of 7.75%. This contributed to the annual value of $9.3 million for FY2024, which is 13.31% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Gains from Investment Securities is -$10,000, which was down 100.43% from $2.3 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Gains from Investment Securities high stood at $10.7 million for Q1 2025, and its period low was -$480,000 during Q2 2021.
  • For the 3-year period, 4D Molecular Therapeutics' Gains from Investment Securities averaged around $4.3 million, with its median value being $2.9 million (2023).
  • Within the past 5 years, the most significant YoY rise in 4D Molecular Therapeutics' Gains from Investment Securities was 22,120.04% (2021), while the steepest drop was 16,100.00% (2021).
  • 4D Molecular Therapeutics' Gains from Investment Securities (Quarterly) stood at $480,000 in 2021, then plummeted by 191.67% to -$440,000 in 2022, then skyrocketed by 879.77% to $3.4 million in 2023, then spiked by 14,321.74% to $10.0 million in 2024, then slumped by 100.10% to -$10,000 in 2025.
  • Its Gains from Investment Securities was -$10,000 in Q3 2025, compared to $2.3 million in Q2 2025 and $10.7 million in Q1 2025.